Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Basic): 2011-2024

Historic EPS (Basic) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $11.86.

  • Agios Pharmaceuticals' EPS (Basic) fell 110.69% to -$1.78 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.98, marking a year-over-year decrease of 159.20%. This contributed to the annual value of $11.86 for FY2024, which is 287.36% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its EPS (Basic) stood at $11.86 for FY2024, which was up 287.36% from -$6.33 recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' EPS (Basic) ranged from a high of $26.55 in FY2021 and a low of -$6.33 during FY2023.
  • Over the past 3 years, Agios Pharmaceuticals' median EPS (Basic) value was -$4.23 (recorded in 2022), while the average stood at $0.43.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 656.60% in 2021, then tumbled by 115.93% in 2022.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' EPS (Basic) stood at -$4.77 in 2020, then surged by 656.60% to $26.55 in 2021, then crashed by 115.93% to -$4.23 in 2022, then plummeted by 49.65% to -$6.33 in 2023, then surged by 287.36% to $11.86 in 2024.